HMGB2 and central nervous system cancer: In TCGA (N = 669), HMGB2 mRNA expression was higher in tumors from the “Glioblastoma multiforme” dataset than in the “Brain Lower Grade Glioma” (T-test p = 9.79 × 10−45—Supplementary Figure S1), and in GBMs compared with other diagnoses, after reclassification according to 2021 WHO (p = 1.65 × 10−59).